Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
3.020
-0.190 (-5.92%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Aquestive Therapeutics Revenue
In the year 2024, Aquestive Therapeutics had annual revenue of $57.56M with 13.80% growth. Aquestive Therapeutics had revenue of $11.87M in the quarter ending December 31, 2024, a decrease of -10.14%.
Revenue (ttm)
$57.56M
Revenue Growth
+13.80%
P/S Ratio
4.55
Revenue / Employee
$405,359
Employees
142
Market Cap
298.59M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.56M | 6.98M | 13.80% |
Dec 31, 2023 | 50.58M | 2.90M | 6.09% |
Dec 31, 2022 | 47.68M | -3.15M | -6.20% |
Dec 31, 2021 | 50.83M | 4.98M | 10.87% |
Dec 31, 2020 | 45.85M | -6.76M | -12.85% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2006 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AQST News
- 3 days ago - Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy - Seeking Alpha
- 22 days ago - Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting - GlobeNewsWire
- 2 months ago - Aquestive Therapeutics: Five Foci For 2025 - Seeking Alpha
- 4 months ago - Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics + - Seeking Alpha
- 5 months ago - Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Aquestive: Rare Opportunity With Dual Platform Strategy - Seeking Alpha